Shares of Amicus Therapeutics Inc. (NASDAQ:FOLD) were down 3.3% during mid-day trading on Wednesday . The stock traded as low as $6.66 and last traded at $6.74, with a volume of 864,544 shares changing hands. The stock had previously closed at $6.97.

Several analysts have issued reports on FOLD shares. Zacks Investment Research raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 target price on the stock in a research report on Monday, July 25th. Chardan Capital set a $15.00 target price on Amicus Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 11th. Leerink Swann reissued an “outperform” rating and issued a $19.00 price objective (up previously from $17.00) on shares of Amicus Therapeutics in a research report on Tuesday, June 14th. Finally, Bank of America Corp. initiated coverage on Amicus Therapeutics in a research report on Wednesday, May 18th. They issued a “buy” rating and a $10.00 price objective for the company. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $12.19.

The stock’s market capitalization is $969.39 million. The stock has a 50-day moving average price of $6.66 and a 200 day moving average price of $6.93.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.07. Equities research analysts forecast that Amicus Therapeutics Inc. will post ($1.35) earnings per share for the current fiscal year.

In other news, insider Jay Barth sold 20,916 shares of the company’s stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $7.00, for a total transaction of $146,412.00. Following the sale, the insider now owns 25,458 shares of the company’s stock, valued at $178,206. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Perceptive Advisors Llc sold 1,100,000 shares of the company’s stock in a transaction on Thursday, August 25th. The stock was sold at an average price of $6.81, for a total value of $7,491,000.00. The disclosure for this sale can be found here.

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.